Back to News
Market Impact: 0.38
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
Source: PR Newswire
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
Phase 3 CERVINO results showed etentamig met both dual primary endpoints—objective response rate and progression-free survival—in relapsed/refractory multiple myeloma. The positive pivotal-study outcome supports the therapy's clinical and potential regulatory trajectory, while additional research presentations may reinforce its broader evidence base.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- Ryanair CEO warns fares could rise by up to 20% in 2027 as fuel bill jumps by $2.2 billion
- The AI trade has broken down. How we got here and what investors should expect next
- Why is Alstom stock down 27% today?
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Kosmos Energy stock sinks on third quarter earnings, revenue miss